










HIV Prevention Research Status Report (July 2016)

Strategy	Status
 Antibodies	<ul style="list-style-type: none"> • Passive immunization trials are looking at safety and efficacy of the VRC01 antibody in Africa and the Americas. • Other antibodies and trials to follow.
 HC/HIV risk	<ul style="list-style-type: none"> • ECHO trial of DMPA (Depo Provera), copper IUD and Jadelle implant launched Q4 2015.
 Long-acting injectable ARV	<ul style="list-style-type: none"> • Two Phase III trials of cabotegravir are planned to start over the next 12 months.
 Multipurpose prevention technologies	<ul style="list-style-type: none"> • 60- and 90-day contraceptive+dapivirine and 60-day contraceptive+tenofovir vaginal rings are furthest ahead in development. • More formulations (e.g., films, inserts) are in development.
 Oral PrEP	<ul style="list-style-type: none"> • Tenofovir-based daily PrEP is safe and effective and is rolling out in many countries. • WHO recommends it for all at substantial risk, September 2015.
 Preventive vaccines	<ul style="list-style-type: none"> • The efficacy trial HVTN 702 builds on previous success—planned launch in Nov 2016. • Janssen Ad26/mosaic candidate—possible efficacy trial in 2017. • Other candidates are in development.
 Rectal gel	<ul style="list-style-type: none"> • First Phase II completed. Reduced glycerin tenofovir gel is safe, well-tolerated. Mixed feedback on applicator and ease of use. • Other candidates and delivery systems are in development.
 Vaginal gel	<ul style="list-style-type: none"> • Tenofovir gel is not being pursued based on data from trials to date. • Other candidates and delivery systems are in development.
 Vaginal ring	<ul style="list-style-type: none"> • Two trials show modest protection with dapivirine ring; key differences among age groups. Open-label extension trials planned/underway. • Other rings for prevention of HIV and/or pregnancy and other STIs are in development.